索辰科技首次公开发行股票的发行费用合计22,172.06万元（不含税），其中保荐承销费用19,231.02 万元。 索辰科技于2023年6月13日披露的2022年年度权益分派实施公告显示，公司本次利润分配及转增股 本以方案实施前的公司总股本41,333,400股为基数，每股派发现金红利0.15元（含税），以资本公积金 向全体股东每股转增0.48股，共计派发现金红利6,200,010元，转增19,840,032股，本次分配后总股本为 61,173,432股。除权（息）日为2023年6月20日。 索辰科技于2024年6月12日披露的2023年年度权益分派实施公告显示，根据2023年年度股东大会决 议通过的利润分配方案，以实施权益分派股权登记日登记的总股本扣除公司回购专用账户中的回购股份 为基数，每10股派发现金红利3.80元（含税），以资本公积向全体股东每10股转增4.60股。股权登记日 为2024年6月18日，除权（息）日为2024年6月19日。 (责任编辑：田云绯) 中国经济网北京2月13日讯 索辰科技(688507.SH)今日收报98.30元，跌幅2.87%，总市值87.59亿 元。该股目前处于破发状态。 ...

Core Viewpoint - The announcement highlights a significant change in the equity holdings of Youyan Silicon, with its controlling shareholder and concerted parties reducing their stake by 1% [1] Group 1: Shareholding Changes - On February 11, 2026, Youyan Silicon's controlling shareholder RS Technologies and its concerted party, Cangyuan Investment, reduced their holdings by a total of 2,362.55 million shares, representing a decrease from 59.19% to 57.30% of total shares [1] - Cangyuan Investment sold 10 million shares through centralized bidding, accounting for 0.80% of the total shares, while RS Technologies and Cangyuan Investment sold 13.6255 million shares through block trading, accounting for 1.09% of total shares [1] Group 2: Financial Performance - In 2023, Youyan Silicon reported total revenue of 960.40 million yuan, a year-on-year decrease of 18.29%, and a net profit attributable to shareholders of 254.18 million yuan, down 27.65% [2] - The company’s net profit after deducting non-recurring gains and losses was 165.00 million yuan, reflecting a significant decline of 47.28% year-on-year [2] - For 2024, total revenue increased to 995.95 million yuan, a growth of 3.70%, but net profit decreased by 8.37% to 232.90 million yuan [3] - In 2025, total revenue was reported at 1,005.25 million yuan, a slight increase of 0.93%, while net profit fell by 10.14% to 209.28 million yuan [3] Group 3: Initial Public Offering (IPO) Details - Youyan Silicon was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on November 10, 2022, with an initial issuance of 187,143,158 shares at a price of 9.91 yuan per share [2] - The total funds raised from the IPO amounted to 1,854.59 million yuan, with a net amount of 1,663.97 million yuan after deducting issuance costs [2] - The company planned to use the raised funds for projects related to 8-inch silicon wafer expansion, silicon materials for integrated circuit etching equipment, and to supplement R&D and operational funds [2]

索辰科技首次公开发行股票募集资金总额253,746.97万元，募集资金净额为231,574.91万元。索辰科技最 终募集资金净额比原计划多134,684.55万元。索辰科技于2023年4月12发布的招股说明书显示，该公司拟 募集资金96,890.36万元，用于研发中心建设项目、工业仿真云项目、年产260台DEMX水下噪声测试仪 建设项目、营销网络建设项目、补充流动资金。 索辰科技首次公开发行股票的发行费用合计22,172.06万元(不含税)，其中保荐承销费用19,231.02万元。 索辰科技于2023年6月13日披露的2022年年度权益分派实施公告显示，公司本次利润分配及转增股本以 方案实施前的公司总股本41,333,400股为基数，每股派发现金红利0.15元(含税)，以资本公积金向全体股 东每股转增0.48股，共计派发现金红利6,200,010元，转增19,840,032股，本次分配后总股本为61,173,432 股。除权(息)日为2023年6月20日。 中国经济网北京2月6日讯索辰科技(688507.SH)今日收报96.93元，跌幅2.14%。该股目前处于破发状 态。 索辰科技于2023年4月18日在上交 ...

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -102 million RMB and -147 million RMB, indicating a reduction in losses by 143.6 million RMB to 188.6 million RMB compared to the previous year, representing a year-on-year loss reduction of 49% to 65% [1] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -106 million RMB and -151 million RMB, with a loss reduction of 149.2 million RMB to 194.2 million RMB compared to the previous year, also reflecting a year-on-year loss reduction of 50% to 65% [1] - The company's operating revenues for 2022, 2023, and 2024 were 559 million RMB, 394 million RMB, and 546 million RMB respectively, with net profits attributable to shareholders of -15.15 million RMB, -54.18 million RMB, and -291 million RMB for the same years [1] IPO and Fundraising - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 21, 2022, with an initial public offering of 40.01 million shares, accounting for 10% of the total shares post-IPO, at a price of 33.57 RMB per share [2] - On the first day of trading, the stock reached a maximum price of 51.88 RMB, but is currently in a state of decline [3] - The total funds raised from the IPO amounted to 1.343 billion RMB, with a net amount of 1.221 billion RMB after deducting issuance costs, exceeding the original plan by 640 million RMB [3] Use of Proceeds - The company plans to use the raised funds for the research and industrialization of high-performance power management chips for consumer electronics and communication devices, the development of next-generation automotive and industrial power management chips, the establishment of a headquarters base, and for working capital [3] Underwriters and Shareholding - The total issuance costs amounted to 122 million RMB, with underwriting and sponsorship fees of 102 million RMB received by the underwriters [4] - The joint lead underwriters, including Guolian Minsheng Securities and China International Capital Corporation, received allocations of 1.6004 million shares each, representing 4% of the total shares issued [4]

中国经济网北京2月4日讯福昕软件(688095.SH)今日收报96.09元，跌幅7.37%。 福昕软件于2020年9月8日在上交所科创板上市，发行数量为1204万股，发行价格238.53元/股，保荐机 构为兴业证券，保荐代表人为李蔚岚、黄实彪，联席主承销商为国泰君安证券(现更名为国泰海通证券 股份有限公司)。 福昕软件于2023年6月15日发布的2022年年度权益分派实施公告显示，该公司拟每股现金红利0.5元(含 税)，每股转增0.4股，股权登记日为2023年6月20日，除权(息)日为2023年6月21日。 福昕软件首次公开发行股票的发行费用为2.85亿元，其中保荐及承销费用为2.67亿元。 据福昕软件上市发行结果公告显示，福昕软件跟投机构为兴证投资管理有限公司，最终战略配售数量为 36.12万股，跟投金额为8615.70万元，占发行总量的3%，限售期为24个月。 福昕软件实控人为熊雨前，中国国籍，拥有美国永久居留权。 福昕软件于2022年6月22日发布的2021年年度权益分派实施公告显示，该公司拟每股现金红利0.8元(含 税)，每股转增0.4股，股权登记日为2022年6月27日，除权(息)日为2022年6月 ...

中国经济网北京1月22日讯 卡莱特(301391.SZ)昨日晚间发布公告称，公司近日收到公司控股股东深圳三 涵邦泰科技有限责任公司、实际控制人周锦志之一致行动人深圳纳百川创新企业（有限合伙）（以下简 称"深圳纳百川"）出具的《关于股份减持计划的告知函》。 因自身资金需求，深圳纳百川计划在本次减持计划公告披露之日起15个交易日后的3个月内以集中竞价 方式合计减持卡莱特股份不超过921,075股（占剔除公司回购专用证券账户中持股数量的总股本比例 1.00%），以大宗交易方式合计减持卡莱特股份不超过1,842,151股（占剔除公司回购专用证券账户中持 股数量的总股本比例2.00%）。 经计算，深圳纳百川本次拟减持卡莱特股份不超过2,763,226股。截至减持计划公告披露前最后一个交易 日，即2026年1月21日，卡莱特收报78.77元/股，以此计算，深圳纳百川本次减持金额预计为21,765.93 万元。 截至本次减持计划公告披露之日，深圳纳百川持有卡莱特股份4,373,248股（占卡莱特总股本比例 4.60%，占剔除公司回购专用证券账户中持股数量的总股本比例4.75%）。 2024年和2025年1-9月，卡莱特归属 ...

Group 1 - The core point of the news is that the controlling shareholder RS Technologies and its action-in-concert party, Fujian Cangyuan Investment Co., plan to reduce their holdings in Youyan Silicon by a total of up to 37,500,000 shares, which is no more than 3% of the company's total share capital [1] - RS Technologies intends to reduce its holdings by up to 12,500,000 shares through block trading, accounting for no more than 1% of the total share capital, while Cangyuan Investment plans to reduce its holdings by up to 25,000,000 shares through centralized bidding and block trading, accounting for no more than 2% of the total share capital [1] - The reduction is due to the operational funding needs of the shareholders, and there are specific regulations regarding the maximum number of shares that can be sold within a 90-day period [1] Group 2 - Based on the closing price of 14.47 yuan on January 16, the total amount from the share reduction is approximately 543 million yuan [2] - Youyan Silicon was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on November 10, 2022, with an initial issuance of 187,143,158 shares at a price of 9.91 yuan per share, raising a total of 1.85 billion yuan [2] - The net amount raised after deducting issuance costs was approximately 1.66 billion yuan, which was 663.97 million yuan more than the original plan of 1 billion yuan [2] Group 3 - In 2023, Youyan Silicon reported operating revenue of 960.40 million yuan, a year-on-year decrease of 18.29%, and a net profit attributable to shareholders of 254.18 million yuan, down 27.65% [3] - For 2024, the company achieved total operating revenue of 995.95 million yuan, a year-on-year increase of 3.70%, but the net profit attributable to the parent company decreased by 8.37% to 232.90 million yuan [3] - The net profit excluding non-recurring gains and losses for 2024 was 163.02 million yuan, showing a slight decline of 1.20% [3]

Group 1 - The core point of the news is that Chen Chaohui, a shareholder and senior executive of Ruina Intelligent, plans to reduce his shareholding by selling up to 279,500 shares, which is approximately 0.21% of the company's total equity [1] - Ruina Intelligent's total share capital is 136,000,000 shares, and Chen holds 1,118,000 shares, representing 0.82% of the total [1] - The company confirms that this share reduction will not lead to a change in control or significantly impact its governance structure or future operations [1] Group 2 - Ruina Intelligent raised a total of 1.025 billion yuan from its initial public offering, with a net amount of 917 million yuan after deducting issuance costs [2] - The final net fundraising amount exceeded the original plan by 518 million yuan, which was initially set at 399 million yuan for various projects [2] - The company distributed a cash dividend of 8 yuan per 10 shares for the 2022 fiscal year, totaling 59.51 million yuan, and also increased the share capital by 8 shares for every 10 shares held [2]

Core Viewpoint - The stock of Shenguan Medical (300888.SZ) is currently in a state of decline, closing at 38.08 yuan with a drop of 3.57%, indicating it is below its initial public offering price [1] Group 1: Company Overview - Shenguan Medical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on September 17, 2020, with an issuance of 50 million shares at a price of 74.30 yuan per share [1] - The total funds raised by Shenguan Medical amounted to 3.715 billion yuan, with a net amount of 3.559 billion yuan after deducting issuance costs, which was 2.133 billion yuan more than the original plan [1] Group 2: Fund Utilization - The company initially planned to raise 1.426 billion yuan for projects including high-end dressing production line construction, marketing network development, research and development center establishment, and digital management system project [1] Group 3: Underwriting and Fees - The underwriting institution for Shenguan Medical's IPO was China International Capital Corporation, with representatives Shen Lulu and Wang Haonan, and the total issuance cost was 156 million yuan, of which the underwriting fee was 123 million yuan [1] Group 4: Dividend Distribution - On May 27, 2023, Shenguan Medical announced a cash dividend of 19.00 yuan (including tax) for every 10 shares, along with a capital increase of 4 shares for every 10 shares, based on a total of 419,737,649 shares after deducting repurchased shares [1]

Group 1 - The core point of the article is that Weiyuan Co., Ltd. (维远股份) has announced that its performance for 2025 is expected to be below expectations due to factors such as declining product prices, leading to a projected net loss for the year [1] - Weiyuan Co., Ltd. was listed on the Shanghai Stock Exchange on September 15, 2021, with an initial public offering of 138 million shares at a price of 29.56 yuan per share, and the stock is currently trading below its initial offering price [1] - The total amount raised from the initial public offering was 4.065 billion yuan, with a net amount of 3.88 billion yuan after deducting issuance costs, which was 2 billion yuan more than originally planned [1] Group 2 - In 2024, Weiyuan Co., Ltd. achieved an operating revenue of 9.522 billion yuan, representing a year-on-year increase of 35.06%, while the net profit attributable to shareholders decreased by 42.62% to 56.59 million yuan [2] - The company's net profit after deducting non-recurring gains and losses was 45.31 million yuan, down 36.85% year-on-year, while the net cash flow from operating activities increased by 49.52% to 918 million yuan [2]